Actively Recruiting
Understanding Quality of Life and Symptoms in Adults Treated for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Led by H. Lee Moffitt Cancer Center and Research Institute · Updated on 2026-04-01
100
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying how quality of life, fatigue, and symptoms change over two years in adults treated for chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study compares two types of drug treatments to help future patients understand what to expect during their care. This observational study is sponsored by the H. Lee Moffitt Cancer Center and Research Institute. Participants receive one of two treatments a Brutons tyrosine kinase inhibitor BTKi or a B-Cell Lymphoma 2 Protein Inhibitor BCL2i, sometimes combined with an anti-CD20 monoclonal antibody or Obinutuzumab. The study includes patients starting these treatments and follows them over a two-year period to observe health outcomes related to their therapy. During the study, participants will be regularly assessed for health-related quality of life HRQOL and factors that may predict these outcomes, along with interactions with their treatment. Patient symptoms, fatigue, and quality of life will be monitored up to two years to gather comprehensive information. The study does not involve experimental treatments but observes patients as they undergo standard therapies.
CONDITIONS
Brief Title
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
Research Team
D
Daniel Lastorino
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here